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ABSTRACT
We retrospectively evaluated the outcomes of 37 adult patients with acute lymphoblastic leukemia (ALL) under-
going allogeneic hematopoietic stem cell transplantation (allo-SCT) conditioned withmedium-dose VP-16 (VP,
30 mg/kg), cyclophosphamide (CY, 120 mg/kg), and fractionated total-body irradiation (TBI, 12 Gy) (medium-
dose VP/CY/TBI). The median age of the patients was 26 years. Thirteen patients underwent transplantation
from HLA-matched related donors (MRD), 18 patients underwent transplantation from HLA-matched unre-
lated donors (MUD), and 6 patients underwent transplantation from HLA-mismatched donors (MMD).
Thirty-two patients received bone marrow and 4 patients received peripheral blood stem cells. Ten patients
were Philadelphia chromosome-positive (Ph1) and 35 patients were in complete remission (CR) at transplanta-
tion. All of the patients achieved engraftment, and grade 3 organ toxicity before engraftment occurred in 27 pa-
tients. Grade II-III acute graft-versus-host disease (GVHD) and chronic GVHD (cGVHD) occurred in 15 and
18 patients, respectively. No patient developed grade IV acute GVHD (aGVHD) or died of GVHD. At median
follow-up of 35.1 months, 32 patients were alive and all Ph1 patients were alive. Three patients died of relapse
and 2 died of transplant-related mortality (TRM). The actuarial 3-year overall survival (OS) rate, relapse rate,
and TRM rate were 89.2%, 8.1%, and 5.4%, respectively. Non-CR at transplantation, MRD, and no aGVHD
were significant adverse prognostic factors for survival. Medium-dose VP/CY/TBI for adult ALL patients was
associated with lower relapse rate and no increase in toxicity, resulting in better survival.
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Although complete remission (CR) has been in-
duced by multiagent chemotherapies in the majority
of patients with acute lymphoblastic leukemia (ALL),
prognosis for adult ALL has not been satisfactory due
to a high rate of relapse [1-5]. Allogeneic hematopoietic568stem cell transplantation (allo-SCT) has been widely
used as postremission therapy, especially for patients
with high-risk ALL [6-8]. Even in patients treated
with allo-SCT using a standard regimen of cyclophos-
phamide with total-body irradiation (CY/TBI), relapse
has been a significant cause of death [7-12]. Various
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mens using VP-16 (VP) combined with CY/TBI (VP/
CY/TBI), have therefore been developed [13-21].
Theuse of some intense regimens resulted in better dis-
ease control, but higher rates of toxicity and transplant-
related mortality (TRM) have also been reported. We
speculated that the high rates of TRM in these studies
were mainly due to the doses of VP (45-60 mg/kg).
Recently, we reported successful outcomes of patients
with various kinds of hematologicmalignancies treated
with a medium-dose VP (30 mg/kg) /CY/TBI regimen
at Hokkaido University Hospital in Japan: all of the
11 patients with adult ALL were alive after a median
follow-up period of 77.0 months, and the actuarial
5-year disease-free survival (DFS) rate was 100% [22].
In this retrospective study, we confirmed the safety
and efficacy of the medium-dose VP/CY/TBI regimen
for 37 patients with adult and adolescent ALL or re-
lated disorders and revealed suitable patients for this
regimen.
PATIENTS AND METHODS
Patients
We studied outcomes in a consecutive series of 37
adult or adolescent patients diagnosed with ALL,
acute biphenotypic leukemia (ABL), or T cell lympho-
blastic lymphoma (T-LBL) who underwent allo-SCT
using a conditioning regimen of medium-dose VP/
CY/TBI during the period from 1993 to June 2007
at Hokkaido University Hospital. We have been using
this regimen for all adult ALL patients without any in-
tentional selection, and all of the patients in whom this
regimen was used were included in this study. Data for
patients with Burkitt leukemia (FAB classification: L3)
were excluded from analysis because Burkitt leukemia
is defined as a different category from ALL in the
World Health Organization (WHO) classification.
Almost all of the patients received mutiagent chemo-
therapies (CY, vincristine, doxorubicin, L-asparaginase,
and glucocorticoid) as an induction therapy, and 7 of
the 10 Philadelphia chromosome-positive (Ph1) pa-
tients were treated with chemotherapies that included
imatinib prior to allo-SCT. No patient was exposed to
VP as an induction therapy, but 15 patients received 1
course of consolidation therapy that included VP at
a dose of 100 mg/m2 daily for 4 or 5 days (total dose:
400 mg/m2 or 500 mg/m2).
Conditioning Regimen
All patients received medium-dose VP/CY/TBI.
This regimen consisted of VP at a dose of 15 mg/kg
once daily administered intravenously (i.v.) on days
27 and 26 (total dose: 30 mg/kg) and CY at 60 mg/kg
once daily i.v. on days25 and24 (total dose: 120 mg/kg)
combined with fractionated TBI at 2 Gy twice daily
on days 23 to 21 (total dose: 12 Gy). Until 2000,graft-versus-host disease (GVHD) prophylaxis con-
sisted of cyclosporine A and a short course of metho-
trexate (MTX, 15 mg/m2 on day 1 and 10 mg/m2 on
days 3 and 6) for all of the patients. Since 2001, cyclo-
sporine A plus MTX has been given for HLA-matched
related donor (MRD) recipients and tacrolimus plus
a short course of MTX has been given for HLA-
matchedunrelateddonor (MUD)orHLA-mismatched
donor (MMD) recipients. GVHD prophylaxis was
administered for 3 months and then tapered in patients
with no active GVHD, and the dose of cyclosporine A
or tacrolimus was adjusted by plasma level.
Supportive Care
Granulocyte colony-stimulating factor was admin-
istered from day 1 until engraftment. A standard reg-
imen of antibiotic prophylaxis was used to prevent
bacterial, viral, fungal, and Pneumocysitis jiroveci infec-
tions. Treatment of mucosal injury and neutropenic
fever was performed in accordance with standard prac-
tice guidelines. Surveillance blood antigenemia for
cytomegalovirus was monitored twice weekly between
engraftment and day 100 post-SCT, and patients
received preemptive ganciclovir at onset of cytomega-
lovirus antigenemia.
Evaluation of Response
In this study, high-risk ALL patients were defined
as those with at least 1 of the following risk factors:
Ph1, ABL, age $35 years old, white blood count
(WBC) .3.0  1010/L for B lineage and .10 
1010/L for T lineage at diagnosis, and time to CR of
.6 weeks. Patients with T-LBL were excluded from
this risk stratification. Neutrophil engraftment and
platelet engraftment were defined as the first of 2
days with absolute neutrophil count .0.5  109/L
and the first of 7 days with an untransfused platelet
count .50  109/L, respectively. Toxicity after SCT
was graded by the National Cancer Institute (NCI)
common toxicity criteria (NCI, Bethesda, MD). Acute
GVHD (aGVHD) and chronic GVHD (cGVHD)
were graded by standard criteria. Serial samples of
peripheral blood or bone marrow were monitored for
hematopoietic chimerism by using polymerase chain
reaction (PCR)-based analyses of short tandem re-
peats. In some patients, minimal residual disease was
assessed by using the PCR method for detecting
BCR-ABL fusion gene or case-specific immunoglobu-
lin heavy chain orT cell receptor rearrangement, as de-
scribed previously [23]. In brief, bone marrow samples
were collected at the time of initial diagnosis andDNA
was extracted. DNA samples were amplified by the
seminested PCR procedure using amplimers for clonal
VH-JH for IgH, Vg-Jg for TCR g, and nested PCR
detecting each VDJd1-TCR recombination and Vd2-
Dd3 recombination for TCR d gene rearrangements.
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mens from patients, genomic DNA from leukemic
cells at the time of initial diagnosis was compared
with that from leukemic cells obtained before and after
SCT.
Statistical Analysis
Overall survival (OS) was calculated from the day
of SCT until death or last follow-up. The probability
of OS was estimated using the Kaplan-Meier method.
Relapse and TRM rates were estimated using cumula-
tive incidence analysis and considered as competing
risks. The effects of various patient and disease cate-
goric variables on survival probabilities were studied
using the log-rank test. All P-values were 2-sided and
a P-value of .05 was used as the cutoff for statistical
significance.
RESULTS
Patients and Transplant Characteristics
Patients and transplant characteristics are summa-
rized in Table 1. Themedian age of the patients was 26
years (range: 15-58 years). Twenty-eight (75.7%) of
the patients had ALL (B cell: 64.9%, T cell: 10.8%),
4 (10.8%) had ABL and 5 (13.5%) had T-LBL. Cyto-
genetic study was performed in 31 patients (83.8%) at
diagnosis and Ph was positve in 10 (32.3%) of those
patients. Twenty-one (68.8%) of the 32 evaluable pa-
tients were at high risk: age .35 years (13 patients,
35.1%), Ph1 (mentioned above), ABL (4 patients,
12.5%), WBC .3.0  1010/L for B lineage at diagno-
sis (6 patients, 18.8%) and time to CR .6 weeks
(7 patients, 21.9%). Central nervous system involve-
ment of leukemia during the course of disease was
seen in 3 patients (8.1%). Thirty-five (94.6%) of the
patients were in CR at the time of SCT, 75.7% in first
CR (CR1), and 18.9% in second CR (CR2). Only 2 pa-
tients were not in CR (non-CR). The BCR-ABL fusion
gene was undetectable in 4 Ph1 patients at the time of
transplant. Patients received allo SCT from an MRD
(13 patients, 35.1%), MUD (18 patients, 48.6%), or
MMD (6 patients, 16.2%), and 32 patients (86.5%)
received bone marrow.
Engraftment
All patients engrafted with median neutrophil
recovery at day 16 (range: 8-25 days) and 34 patients
engrafted with median platelet recovery at day 27
(range: 18-74 days). Results of engraftment analysis us-
ing short tandem repeats were available for 20 patients,
showing 100% donor chimerism in all of them with
median time of 100% chimerism being day 28 (range:
12-49 days). No recipient developed secondary graft
failure.Disease Control
Posttransplant bone marrow studies were not per-
formed in 2 patients because of early deaths. None of
the remaining 35 patients showed evidence of residual
disease by morphology or cytogenetics. In 11 patients
with morphologic CR but with minimal residual dis-
ease (PCR1 CR) at the time of transplant, 10 patients
(90.9%) became PCR-negative (PCR2 CR) after
transplant and the remaining patient had persistent
PCR positivity with no relapse. All Ph1 patients were
Table 1. Patient and Transplant Characteristics
n (%)
Total 37
Median age (range) 26 (15.58)
Age $ 35 13 (35.1%)
Age $ 40 7 (18.9%)
Sex
Male 20 (54.1%)
Female 17 (45.9%)
Diagnosis
B-ALL 24 (64.9%)
T-ALL 4 (10.8%)
ABL 4 (10.8%)
T-LBL 5 (13.5%)
Philadelphia chromosome* 10 (32.3%)
WBC .31010 for B-ALL† 6 (18.8%)
WBC .101010 for T-ALL† 0 (0.0%)
Time to CR .6 weeks† 7 (21.9%)
Disease risk†
Standard 10 (31.3%)
High 22 (68.8%)
CNS involvement during course 3 (8.1%)
Disease status at transplantation
CR 35 (94.6%)
CR1 28 (75.7%)
CR2 7 (18.9%)
non-CR 2 (5.4%)
Minimal residual disease at
transplantation in CR patients
PCR1 11 (31.4%)
PCR– 9 (25.7%)
N.D. 15 (42.9%)
Donor
MRD 13 (35.1%)
MUD 18 (48.6%)
MMRD 2 (5.4%)
MMUD 4 (10.8%)
Stem cell source
Bone marrow 32 (86.5%)
Peripheral blood stem cell 4 (10.8%)
Cord blood 1 (2.7%)
GVHD prophylaxis
CSP1MTX 28 (75.7%)
TK1MTX 9 (24.3%)
All indicates acute lymphoblastic leukemia; ABL, acute bi phenotypic
leukemia; T-LBL, T cell lympho plastic lymphoma; MRD,
matched related donor; MUD,matched unrelated donor; MMD,
mismatched donor; CR, complete remission; WBC, white blood
cell; MMRD, mismatched related donor; MMUD, mismatched
unrelated donor.
*Cytogenetic study was performed in 31 patients.
†Five patients with T-LBL were excluded from risk stratification.
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all of the 6 Ph1 patients who were PCR-positive at
transplantation became PCR-negative after allo-
SCT. Therefore, no patients received imatinib after
SCT. Only 3 patients (8.1%) relapsed after allo-SCT
on days 95, 113, and 564, respectively, and all of
them died (Figure 1a). Two of the 3 patients with ear-
lier relapse had T-LBL and the other had B-ALL.
These patients were in PCR2 CR1 at transplantation,
and 2 (40%) of the 5 T-LBL patients relapsed.
Toxicity and GVHD
Table 2 shows a summary of organ toxicity and
GVHD.Toxicity before engraftment could be assessed
in 33 patients but not in 4 patients because of insuffi-
cient medical records. NCI grade$3 nonhematologic
organ toxicity occurred in 27 patients (81.8%). NCI
grade 3 stomatitis and diarrhea were common findings,
occurring in 19 patients (57.6%) and 11 patients
(33.3%), respectively. Febrile episodes were also com-
mon during the neutropenic period, occurring in 23
patients (69.7%). Although blood cultures and chest
X-rays were frequently performed, pathogens of the
fever could be detected in only 4 patients. Cardiovascu-
lar toxicity (congestive heart failure), pulmonary toxic-
ity, hepatic toxicity including veno-occulusive disease
(VOD) and transplant-related thrombotic microangi-
opathy occurred in 2 patients (6.1%), 1 patient (3%),
3 patients (9.1%), and 2 patients (6.1%), respectively.
A clinical diagnosis of VOD could be made by the
Jones criteria in only two patients (6.1%), and 1 of
them, who had active disease at transplantation, died
of hepatic failure on day 27. One patient of relatively
advanced age (58 years old) died of respiratory failure
due to interstitial pneumonitis of unknown etiology
on day 48. Total and grade II–III aGVHD occurred
in 29 and 15 patients with cumulative incidences of
78.4% and 40.5%, respectively. No patient developed
grade IV aGVHD. Median onset day of aGVHD was
day 19 (range: 7-59 days). Chronic GVHD occurred
in 18 of the 33 evaluable patients, extensive in 12 pa-
tients, and limited in 6 patients (cumulative incidence:
54.5%), at median day 118 (range: 48-254 days). No
patient died of complications related to aGVHD or
cGVHD, and no secondary malignancy was observed
during the follow-up period. TRM occurred in only
2 patients with a cumulative incidence of 5.4% at
3 years after SCT (Figure 1b).
Figure 1. Cumulative incidence of relapse (a), TRM (b), and OS (c).
TRM indicates transplant-related mortality; OS, overall survival.
Table 2. Organ Toxicities and GVHD
No (%)
Organ toxicity*
Any grade 3 toxicity 27 (81.8%)
Stomatitis 19 (57.6%)
Diarrhea 11 (33.3%)
Cardiovascular 2 (6.1%)
Pulmonary/DAH 1 (3.0%)
Hepatic 3 (9.1%)
VOD 2 (6.1%)
TMA 2 (6.1%)
Death due to organ toxicity 2 (5.4%)
Febrile episode before engraftment 23 (69.7%)
GVHD†
Acute GVHD total 29 (78.4%)
Acute GVHD grade II-IV 15 (40.5%)
Chronic GVHD total 18 (54.5%)
Chronic GVHD extensive 12 (36.4%)
Death due to GVHD 0 (0.0%)
DAH indicates diffuse alveolar hemorrhage; VOD, veno-occlusive
disease of the liver, TMA, thrombotic microangiopathy.
*Toxicity is graded by NCI common toxicity criteria. Only patients
with grade 3 toxicity are presented. Some patients had toxicity in
more than one organ system. Organ toxicity was evaluated in 33
patients.
†Acute GVHD and chronic GVHD were evaluted in 37 and 33
patients, respectively.
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At the end of a median follow-up period of 35.1
months (range: 0.9-163.2 months), 32 patients were
alive and 5 had died. Two patients died of treatment-
related complications before day 100 and 3 patients
died of disease relapse. The actuarial 3-year OS and
5-year OS rates were 89.2% and 86.5%, respectively
(Figure 1c). The 3-year OS rates for allo-SCT at
CR1, CR2, and non-CR were 92.6%, 85.7%, and
50%, respectively. OS rates were 92.9% for patients
with ALL, 100% for those with ABL, and 60% for
those with T-LBL. All Ph1 patients were alive and
OS rate was 83.3% for those without Ph. OS rates
for patients with aGVHD and those without aGVHD
were 93.1% and 75.1%, respectively, and OS rates for
patients transplanted from MRDs and those from
MUDs were 76.9% and 100%, respectively. Table 3
shows the results of univariate analysis of factors influ-
encing OS. Univariate analysis revealed non-CR at
transplantation (P \ .01), MRD (P 5 .01) and no
aGVHD (P5 .02) to be significant adverse prognostic
factors for OS. Although not statistically significant,
diagnosis of T-LBL (P 5 .06) or no cGVHD (P 5
.08) tended to have an adverse impact on OS. Age, pa-
tient’s sex, central nervous system involvement, disease
risk, type of CR (CR1 or CR2, PCR1 or PCR2) and
GVHD prophylaxis were not predictive factors for
the outcome.
DISCUSSION
Wehave previously reported the safety and efficacy
of medium-dose VP/CY/TBI as a conditioning regi-
men of allo-SCT for hematologic malignancies [22].
In the current study, focusing on adult patients with
ALL, engraftment was achieved in all patients. Al-
though grade 3 stomatitis and febrile episodes in the
neutropenic period were common, severe GVHD
and TRM were not increased compared with those in
previous studies [7-12]. The 3-year OS of 89.2% in
our case series compares favorably with the results of
other studies using a standard conditioning regimen
of CY/TBI [7-12], our good results being because of
reduction in relapse. In the LALA-94 trial, patients in
CR1 with MRD were allocated to allo-SCT using
CY/TBI. In the patients treated with allo-SCT,
3-year TRM rate, 3-year relapse rate, and 3-year dis-
ease-free survival (DFS) rate were 18%, 34%, and
47% respectively [10], indicating that relapse was the
main cause of death even after allo-SCT. There have
been many reports on intensified conditioning regi-
mens of allo-SCT including high-dose VP (60 mg/kg
or 1.5-1.8 g/m2) /CYTBI for the purpose of reduction
in relapse rate [13-22]. Most of those studies using VP/
CY/TBI included patients with various kinds of hema-
tologic malignancy, but our study was limited to adult
ALL. In our study, relapse occurred in only 3 patients(8.1%), indicating much better disease control than
that of CY/TBI or other regimens. Although our pa-
tients with GVHD showed better outcome than those
without GVHD, which may suggest a graft-versus-
leukemia (GVL) effect, better disease control in this
study was thought to be mainly due to eradication of
residual disease by the conditioning regimen. The rea-
sons are that GVL effect has been reported to have lim-
ited efficacy for ALL patients, occurrence of aGVHD
or cGVHD in our study was the same as that in other
studies, and PCR1 CR patients at transplantation
became PCR2 CR soon after allo-SCT, suggesting
a direct antitumor effect of the conditioning regimen.
Although Ph1 patients have been reported to have
a poorer outcome than that of Ph2 patients after allo-
SCT [10,24,25], all Ph1 patients in our studywere alive
without relapse. Furthermore, some studies have
shown that the outcome for patients in CR2 at trans-
plantation was worse than that for patients in CR1
[26-28], but the outcomes of patients in CR1 and
CR2 in the present study were comparable. Marks
et al. [29] reported that a VP/TBI regimen showed bet-
ter disease control than that of standard-dose CY/TBI
for patients with ALL in CR2, indicating that VP has
better anti-ALL activity than that of CY.
The rate of TRM in this study was also very low,
occurring in only two patients (5.3%), and no patient
died before engraftment despite the high rate of muco-
sal injury or febrile episodes. Furthermore, although
there have been reports that aGVHD is related in
part to cytokine release from damaged gastrointestinal
tissues, incidence and severity of aGVHD in this study
did not increase, and no patient died of GVHD. The
dose used in VP/CY/TBI regimens in previous studies
(60mg/kg or 1.5-1.8 g/m2) was higher than that used in
our regimen, and the rate of TRM was higher in those
studies (28%-47%), pulmonary toxicity (pulmonary
hemorrhage and interstitial pneumonitis), and liver
toxicity including VOD being the main causes of death
[13-22]. Giralt et al. [14] and Yau et al. [16] reported
that rates of TRM were 32.9% and 27.9%, respec-
tively, and that incidences of diffuse alveolar hem-
orrhage causing death were 8% and 7%, respectively.
In our study, only 1 patient (58 years old) died of inter-
stitial pneumonitis, and no patient experienced diffuse
pulmonary hemorrhage. Three patients developed
grade 3 liver toxicity and 2 of them had VOD, and 1
of them with active disease died of hepatic failure due
to VOD. Peterson et al. [15] and Spitzer et al. [20]
reported that a lower dose of VP was associated with
reduction in TRM, and we speculated that the differ-
ence betweenTRM in our study and that in other stud-
ies using VP/CY/TBI is mainly because of the dose of
VP [22]. Although the dose of VP seemed to be impor-
tant, TRMof 5.8% in this study was unexpectedly low.
We have used a medium-dose VP/CY/TBI regimen
for a total 92 patients with various kinds of hematologic
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n Alive (%) HR (95%CI) P-value*
Age
\40 30 27 (90.0%) 0.79 (0.07-8.25) 0.83
$40 7 6 (85.7%)
Sex
Male 20 18 (90.0%) 0.59 (0.10-3.41) 0.55
Female 17 14 (82.4%)
Diagnosis
non T-LBL ALL 28 25 (89.3%) 0.21 (0.01-1.10) 0.06
ABL 4 4 (100%)
T-LBL 5 3 (60.0%)
Philadelphia chromosome
Yes 10 10 (100%) 0.00 (0.04-1.68) 0.15
No 24 19 (79.2%)
Disease risk
Standard 10 9 (90.0%) 0.82 (0.07-8.95) 0.87
High 22 20 (90.9%)
CNS involvement during course
Yes 3 2 (66.7%) 1.17 (0.21-152.93) 0.30
No 34 30 (88.2%)
Disease status at transplantation
non-CR 2 1 (50.0%) 10.90 (9.78-1.5106) \0.01
CR 35 31 (88.6%)
CR1 28 25 (89.3%) 0.79 (0.07-8.69) 0.83
CR2 7 6 (85.7%)
PCR1CR 9 8 (88.9%) 1.17 (0.07-19.09) 0.91
PCR-CR 11 10 (90.9%)
Donor
MUD 13 13 (100%) 0.00 (0.01-0.61) 0.01
MRD 18 14 (77.8%)
Acute GVHD prophylaxis
CSP1MTX 28 24 (85.7%) 1.00 (0.11-9.03) 1.00
TK1MTX 9 8 (88.9%)
Acute GVHD
Yes 29 27 (93.1%) 0.15 (0.01-0.62) 0.02
No 8 5 (62.5%)
Chronic GVHD
Yes 18 18 (100%) 0.00 (0.00-1.37) 0.08
No 15 13 (86.7%)
HR indicates hazard ratio; 95%CI, 95% confidence interval.
*Stastical analysis on OS was studied with the log-rank test.malignancy and TRM rate was 15.2% (data not
shown). Risk factors for TRM in this population
were age $40 years (age\40 years: 8.7% versus age
$40 years: 33.3%, P5 .001) and non-CR at transplan-
tation (CR: 10.8% versus non-CR: 25.9%, P\ .001).
Duerst et al. [21] reported that older age and advanced
disease at transplantation were themain risk factors for
TRM in their analysis of allo-SCT usingmedium-dose
VP/CY/TBI for children with acute leukemia. In the
current study, a smaller number of patients had these
risk factors: 7 patients (19%) were older than 40 years
and 2 patients (6%) were not in CR at transplantation,
accounting for the unexpectedly low rate of TRM.The
younger age of our patients may also explain our good
results because of excellent disease control. Many clin-
ical trials have shown higher remission rate and better
prognosis among younger patients because of different
biologic characteristics of leukemic cells and lower rate
of complications despite intensified chemotherapy[30-33]. In our study, among 23 patients under the
age of 30 years, 16 patients (69.6%) received SCT in
CR1 and only 2 patients died due to disease progres-
sion. Two of the 3 patients with Ph were treated with
imatinib before SCT, and 3 very young patients (\25
years of age) were treated using an intensified regimen
like that used for childhood ALL. Nine patients re-
ceived consolidation chemotherapies, which included
high-dose cytarabine and high-dose MTX, and no pa-
tients developed central nervous system leukemia dur-
ing the follow-up period. These developments in
treatment strategy before SCT may also have contrib-
uted to the good results of our study.
A special consideration when using VP is second-
ary malignancies. Although VP is an active agent in
ALL,many studies, mostly conducted in pediatric cen-
ters, have shown an increased risk of therapy-related
leukemia and other malignancies by using VP [34-
35], and VP has therefore been removed from most
574 A. Shigematsu et al.induction regimens [35]. However, second malignancy
should not be an issue with allo-SCT, and no patients
in the present study developed secondmalignancy dur-
ing a median follow-up period of 35.1 months. There-
fore, this conditioning regimen for ALL would be an
ideal venue to reintroduce this drug.
Although our analysis has limitations because of its
retrospective fashion and small sample size, a medium-
dose VP/CY/TBI regimen seems to be a promising
treatment for adult patients with ALL, and a prospec-
tive study on this regimen for adult ALL is warranted.
Although age was not a risk factor for survival in our
analysis limited to ALL, age $40 years and non-CR
at transplantation have been reported as risk factors
for TRM, and we confirmed that patients with these
risk factors were also at high risk for TRM after me-
dium-dose VP/CY/TBI for hematologic malignancies
(not limited to ALL). Therefore, we think that suitable
patients for a prospective study are those aged \40
years and those in CR at transplantation.
In summary, the use of medium-dose VP/CY/TBI
as a conditioning regimen for adult patients with ALL
and related disorders enabled very good disease con-
trol without increase in TRM, resulting in better
survival of patients.
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